Biothera to Present Three Late-Breaking Posters at the American Association for Cancer Research Annual Meeting
April 09 2015 - 10:00AM
Business Wire
Biothera scientists will present four scientific posters at the
world’s largest annual cancer research conference: the American
Association for Cancer Research (AACR) annual meeting April 18-22
in Philadelphia. Three of the posters were selected for the high
profile, late-breaking research sessions—sessions devoted to the
newest, most exciting research of the year.
“We are excited to present the latest research on our
investigational cancer immunotherapy drug Imprime PGG,” said Jeremy
Graff, Ph.D., Senior Vice President Biothera Pharmaceutical
Research. “In addition to Imprime PGG’s role in priming innate
immune effector cells to recognize and kill antibody-coated tumor
cells, the work to be presented highlights a critical role for
Imprime PGG in altering the immune microenvironment and triggering
cross-talk with the adaptive arm of the immune system.”
All three late-breaking poster presentations will be presented
from 1:00 pm – 5:00 pm on Tuesday, April 21 in Section 39 at the
Pennsylvania Convention Center. The presentation titles are as
follows:
- Imprime PGG treatment elicits a
coordinated antitumor immune response that triggers enhanced
expression of PD-L1 on tumor cells as well as monocyte-derived
macrophages and dendritic cells. Abstract number: LB-228.
- Imprime PGG conjugated directly to
protein enables cross-presentation of antigen that generates
multifunctional cytotoxic T cells. Abstract number: LB-236.
- Imprime PGG modulates the function of
monocyte-derived M2 macrophages and dendritic cells to drive T-cell
expansion. Abstract number: LB-225.
Biothera also will present a fourth poster between 8:00 am and
12:00 pm on Wednesday, April 22 in section 11, poster board number
26.
- Imprime PGG decreases regulatory T cell
suppression and enhances T cell proliferation and differentiation
revealing additional mechanisms for its anti-tumor activity.
Abstract Number: 5034
About Biothera
Biothera, a privately held U.S. biotechnology company, is
developing Imprime PGG, a late clinical stage biologic that
modulates the immune response to cancer. Data from the most recent
randomized phase 2 study of Imprime PGG in first line non-squamous
non-small cell lung cancer (NSCLC) was featured as a late-breaking
abstract in the Immunotherapy of Cancer session at ESMO 2014. In
this study, which evaluated the addition of Imprime PGG to
bevacizumab and carboplatin/paclitaxel versus bevacizumab and
chemotherapy alone, objective response rate was 60.4% versus 43.5%,
duration of response was 10.3 months versus 5.6 months and median
overall survival was 16.1 months versus 11.6 months. Similarly
encouraging data have been observed in both squamous and
non-squamous subjects in a second randomized Phase 2 study in 1st
line NSCLC in combination with cetuximab and in studies in
high-risk chronic lymphocytic leukemia and metastatic colorectal
cancer. Imprime PGG is being evaluated in a phase 3 study in late
stage metastatic colorectal cancer and planning is underway for an
approvable study in NSCLC. Emerging research further shows that
Imprime PGG can re-orient the larger immune microenvironment,
affecting both innate and adaptive immune effector cells, including
T cells, dendritic cells, macrophages and myeloid-derived
suppressor cells.
More information is available at www.biothera.com/pharma or
follow us on Twitter.
Biothera, the Immune Health CompanyDavid Walsh, 651-256-4606SVP
Marketing & Communicationsdwalsh@biothera.com